G 
1.00
+0.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Geron
From its filings with the US Securities and Exchange Commission
Geron is based in Foster City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GERN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $237,000.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Jul 1996
- Employees
- 258
- Website
- geron.com ↗
- Head office
- 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Elizabeth O'FarrellLead Independent Chairman of the Board$630,749
- Mr. Harout SemerjianPresident, Chief Executive Officer, Director, since 2025
- Ms. Michelle RobertsonChief Financial Officer, Executive Vice President - Finance, Treasurer$2.1m
- Dr. Andrew GrethleinExecutive Vice President, Chief Operating Officer$2.2m
- Ms. Shannon OdamChief People Officer, Senior Vice President
- Mr. Scott SamuelsExecutive Vice President, Chief Legal Officer, Secretary$3.6m
- Ms. Melissa BehrsExecutive Vice President - Business Operations, Chief Alliance Officer$1.2m
- Dr. Joseph EidExecutive Vice President - Research and Development$7.2m
- Dr. Faye FellerExecutive Vice President, Chief Medical Officer
- Mr. Edward KovalExecutive Vice President, Chief Business Officer
- Mr. Jim ZieglerExecutive Vice President, Chief Commercial Officer$5.4m
- Ms. Dawn BirDirector, since 2019$583,314
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 46
- Social
- 57
- Governance
- 44
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Geron Corp has a strong track record in the field of stem cell research, which gives them a competitive advantage in the biotechnology industry.
- The company's innovative technologies and therapies have the potential to revolutionize the treatment of various diseases.
- Geron Corp has a robust intellectual property portfolio, providing them with a solid foundation for future growth and revenue generation.
Weaknesses
- One of the main weaknesses of Geron Corp is its heavy reliance on the success of its research and development projects, which can be risky and uncertain.
- The company has a limited product pipeline, which may impact its ability to generate sustainable revenue in the long term.
- Geron Corp also faces regulatory challenges and strict government guidelines in relation to stem cell research, which can impede their progress and limit market opportunities.
Opportunities
- The increasing demand for novel therapies and treatments in the healthcare industry presents a significant opportunity for Geron Corp to expand its market presence.
- Collaboration with other biotechnology and pharmaceutical companies could enhance their research capabilities, accelerate product development, and create new revenue streams.
- The growing aging population worldwide opens up potential markets for Geron Corp's regenerative medicine solutions, targeting age-related diseases.
Threats
- Intense competition within the biotechnology sector poses a threat to Geron Corp's market position and potential market share.
- The constantly evolving regulatory landscape around stem cell research and related therapies may hinder the company's ability to bring their products to market.
- Uncertainty surrounding intellectual property rights and potential legal disputes can negatively impact Geron Corp's business operations and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.